The affordable medicines facility-malaria—A success in peril

The Affordable Medicines Facility-malaria (AMFm) has put into place a bold financing plan for artemisinin-combination therapy in a pilot phase in seven countries covering half the population at risk of malaria in Africa. A report of the AMFm independent evaluation, conducted by ICF International and the London School of Hygiene and Tropical Medicine, describes the success of the programme in the pilot sites: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda, comparing availability and affordability of high-quality artemisinin-combination therapies before and after AMFm launched. Proof of concept was achieved: AMFm increased availability and kept prices low, meeting its initial, ambitious benchmarks in most settings. Despite this overwhelming success, opposition to the programme and dwindling resources for malaria control conspire to cripple or kill AMFm.

• Publication year

  2012

• Venue

  Malaria Journal

• Publication date

  2012-11-08

• Fields of study

  Medicine, Economics, Environmental Science

• Identifiers
  DOI 10.1186/1475-2875-11-370PMID 23137141PMCID 3506461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Piloting the Affordable Medicines Facility-malaria: what will success look like?

  2012cited by this paper
• Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda

  2012cited by this paper
• Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.

  2012cited by this paper
• World malaria report

  2005cited by this paper
• Saving lives, buying time : economics of malaria drugs in an age of resistance

  2004influential reference
• The public health impact of chloroquine resistance in Africa.

  2001cited by this paper

• A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria

  2023cites this paper
• Formal and informal medicine retailers in Sub-Saharan Africa: a scoping review of research trends.

  2022cites this paper
• Towards a re-emergence of chloroquine sensitivity in Côte d’Ivoire?

  2018cites this paper
• Social and cultural complexities of anti-malarial drug circulation: an ethnographic investigation in three rural remote communes of Cambodia

  2017cites this paper
• Assessment of the Implementation of the Affordable Medicines Facility for Malaria at Kpone-On-Sea, Ghana

  2016cites this paper
• Towards subsidized malaria rapid diagnostic tests. Lessons learned from programmes to subsidise artemisinin-based combination therapies in the private sector: a review

  2015influential citation
• Towards subsidized malaria rapid diagnostic tests . Lessons learned from the global subsidy of artemisinin-based combination therapies : a review

  2015influential citation
• Effect of the Affordable Medicines Facility for malaria (AMFm) on the availability of antimalarials in Nigeria

  2015cites this paper
• Has Tanzania Embraced the Green Leaf? Results from Outlet and Household Surveys before and after Implementation of the Affordable Medicines Facility -Malaria

  2014cites this paper
• The Changing Landscape of Malaria Case Management in Uganda: Decades of Struggle with Evolving Malaria Case Management Strategies and Drug Policies

  2014cites this paper
• Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000–2011

  2013cites this paper
• An overview of market shaping for global health Landscape, new developments, and gaps

  year unknowncites this paper